Prot#M16-006: A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease (M16-006)

Project: Research project

StatusActive
Effective start/end date7/23/197/22/22

Funding

  • AbbVie Inc. (Prot#M16-006)